Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07393542 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma

StatusRecruiting
PhasePhase 3
Started2026-02-12
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Sep 2027 → Jan 31, 2028
See other at-risk trials from Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Amendment history

2026-08-12
Study Status, Study Design, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v2
Trial arms changed: 3 → 2
Primary completion pushed: 2027-09 → 2028-01-31
Completion pushed: 2030-06 → 2030-10-31
Enrollment target462→453
Eligibility criteria+6 characters
[...] udy treatment. Subjects with active pulmonary tuberculosis. HaveHistory of severe dry eye, active keratitis, or corneal ulcer, or othe [...]
Secondary endpoints11 to 10 entries
Determine the dose of SHR-A2102 in the second phase, participants included in the dose selection analysis were followed up at 6 months in the last case
2026-02-27
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2026-02→confirmed 2026-02-12
Study sitesdetails revised at 1 of 1 site
2026-01-30
Original filing
The study is being conducted to evaluate the efficacy of SHR-A2102 with adebrelimab versus gemcitabine in combination with cisplatin/carboplatin in previously untreated locally advanced or metastatic urothelial carcinoma.
Trial Details
NCT Number NCT07393542
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Locally Advanced or Metastatic Urothelial Carcinoma
Enrollment 453 participants
Start Date 2026-02-12
Primary Completion 2028-01-31 (estimated)
Study Completion 2030-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-14